Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
The 500-patient Phase 3 trial (JX02002) met its primary endpoint, with a Kaplan Meier analysis shows a statistically significantly greater proportion of patients who self-administered etripamil ...
Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
Milestone® (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an upcoming data presentation on ...
Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Milestone® (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, to take place from September 9-11, 2024 ...